Skip to main content

Table 2 Treatment prior to lenvatinib therapy

From: Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China

 

LEN monotherapy

LEN combination

First-line treatment

27/69%

62/86%

Second-line treatment

12/31%

8/11%

 Sorafenib

12/31%

3/4%

 Apatinib

0

3/4%

 PD-1 antibody

0

2/3%

Third-line treatment

0

2/3%

  1. Data are presented as n/%
  2. LEN, lenvatinib; PD-1, programmed cell death protein-1
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us